Nanjing Reju Therapeutics Inc. has described tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) inhibitors reported to be useful for the treatment of inflammatory-related disorders and cell necrosis-related apoptosis diseases.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Universitat de Barcelona has identified histone-lysine N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors reported to be useful for the treatment of Alzheimer’s disease among others.
Researchers from Cornell University are seeking protection for their invention of a low-cost artificial intelligence (AI)-based platform that analyses low resolution electrocardiogram data and/or photoplethysmography data to accurately and objectively assess pain.
Fox Chase Chemical Diversity Center Inc. and University of Pittsburgh have jointly described new proteolysis targeting chimeras (PROTACs) consisting of Nef (HIV-1)-targeting moiety covalently linked to cereblon (CRBN)-binding moiety.
Jiangsu Nhwa Pharmaceutical Co. Ltd. has patented substituted imidazole derivatives acting as α2-adrenoceptor agonists with sedative and/or analgesic and/or anesthetic and/or anxiolytic activity. As such, they are reported to be potentially useful for the treatment of pain, insomnia and psychiatric disorders.
Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.
Universidade Nova De Lisboa has disclosed rhenium complexes described as potentially useful for the treatment of cancer and gram-positive bacterial infections.
RSS
